Gt biopharma to participate at h.c. wainwright hybrid global investment conference

Brisbane, calif., may 12, 2022 (globe newswire) -- gt biopharma, inc. (nasdaq: gtbp), an immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary tri-specific natural killer (nk) cell engager, trike® protein biologic technology platform, announced that management will present at h.c. wainwright's hybrid global investment conference. the conference will take place may 23-26, 2022 at the fontainebleau, miami beach hotel, miami beach, florida.
GTBP Ratings Summary
GTBP Quant Ranking